Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.
OBJECTIVE
The respiratory effects of nebivolol, a new selective ss(1)-adrenergic blocking agent, and celiprolol, a ss-blocker possessing strong ss(1)-adrenoceptor antagonist and mild ss(2)-agonist properties, were investigated in 12 patients with mild asthma.


METHODS
Changes in several spirometric indexes (FVC, FEV(1), and forced expiratory flow rate at 50% of FVC) were measured. The interaction with the bronchodilator effect of the ss(2)-adrenoceptor-selective agonist albuterol also was investigated.


RESULTS
The effect of both nebivolol and celiprolol on FEV(1) was considered to be significant (p < 0.05). The administration of nebivolol and celiprolol, but not of placebo, elicited a decrease in FEV(1): mean maximum difference for nebivolol, -0.272 L (95% confidence interval [CI], -0.402 to -0.142); mean maximum difference for celiprolol, -0.193 L (95% CI, -0.316 to -0.071); mean maximum difference for placebo, -0.0001 L (95% CI, -0.087 to 0.085). The inhalation of albuterol, up to a dose of 800 microg, significantly (p < 0.05) improved FEV(1), but the values after nebivolol and celiprolol administration were lower than the initial values. Both ss-blockers caused equal changes in heart rate, systolic BP, and diastolic BP.


CONCLUSIONS
There were no significant differences between the respiratory actions of the two active drugs.
Cazzola
M
M
Divisione di Pneumologia e Allergologia, Ospedale A. Cardarelli, Napoli, Italy. mcazzola@qubisoft.it
Noschese
P
P
D'Amato
M
M
D'Amato
G
G
D000284:Administration, Oral; D058671:Adrenergic beta-1 Receptor Antagonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017272:Celiprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D016001:Confidence Intervals; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005540:Forced Expiratory Flow Rates / Q000187:drug effects; D005541:Forced Expiratory Volume / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D010919:Placebos; D013147:Spirometry; D014797:Vital Capacity / Q000187:drug effects
D058671:Adrenergic beta-1 Receptor Antagonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D001993:Bronchodilator Agents; D004983:Ethanolamines; D010919:Placebos; D000068577:Nebivolol; D017272:Celiprolol; D000420:Albuterol